Does the media favor MGX or MBRX?

In the previous week, Metagenomi had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Metagenomi and 3 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.30 beat Metagenomi's score of 0.29 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MBRX or GNTA?

Moleculin Biotech currently has a consensus target price of $22.00, indicating a potential upside of 707.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Moleculin Biotech is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, MBRX or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is MBRX or GNTA more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Genenta Science N/A N/A N/A

Is ATYR or MBRX more profitable?

Moleculin Biotech's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Moleculin Biotech N/A N/A -70.93%

Does the media favor ATYR or MBRX?

In the previous week, Moleculin Biotech had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.61 beat Moleculin Biotech's score of 0.30 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MBRX or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is MBRX or ESLA more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Estrella Immunopharma N/A N/A -397.36%

Does the media prefer MBRX or ESLA?

In the previous week, Moleculin Biotech had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.30 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MBRX or NBRV?

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 707.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Moleculin Biotech (MBRX) Competitors

$2.72 +0.09 (+3.22%)

As of 10:14 AM Eastern

Compare

MBRX vs. MGX, GNTA, ATYR, ESLA, and NBRV

Should you buy Moleculin Biotech stock or one of its competitors? MarketBeat compares Moleculin Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Moleculin Biotech include Metagenomi (MGX), Genenta Science (GNTA), aTyr Pharma (ATYR), Estrella Immunopharma (ESLA), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.

How does Moleculin Biotech compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Metagenomi had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Metagenomi and 3 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 0.30 beat Metagenomi's score of 0.29 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.83	-$87.87M	-$2.30	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Metagenomi has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

15.5% of Moleculin Biotech shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Moleculin Biotech's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Moleculin Biotech	N/A	N/A	-70.93%

Metagenomi currently has a consensus target price of $9.00, suggesting a potential upside of 634.69%. Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 707.34%. Given Moleculin Biotech's higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Metagenomi and Moleculin Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Moleculin Biotech compare to Genenta Science?

Moleculin Biotech (NASDAQ:MBRX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Moleculin Biotech had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.43 beat Moleculin Biotech's score of 0.30 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Genenta Science	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Moleculin Biotech has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Moleculin Biotech currently has a consensus target price of $22.00, indicating a potential upside of 707.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Moleculin Biotech is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Genenta Science	N/A	N/A	N/A

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Moleculin Biotech beats Genenta Science on 6 of the 10 factors compared between the two stocks.

How does Moleculin Biotech compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Moleculin Biotech's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Moleculin Biotech	N/A	N/A	-70.93%

In the previous week, Moleculin Biotech had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.61 beat Moleculin Biotech's score of 0.30 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moleculin Biotech has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	241.00	-$74.12M	-$0.73	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

aTyr Pharma has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

aTyr Pharma presently has a consensus price target of $21.00, indicating a potential upside of 4,396.79%. Moleculin Biotech has a consensus price target of $22.00, indicating a potential upside of 707.34%. Given aTyr Pharma's higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Moleculin Biotech beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does Moleculin Biotech compare to Estrella Immunopharma?

Moleculin Biotech (NASDAQ:MBRX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Moleculin Biotech presently has a consensus price target of $22.00, suggesting a potential upside of 707.34%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 644.19%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Moleculin Biotech has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Estrella Immunopharma	N/A	N/A	-397.36%

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Moleculin Biotech had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.30 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Moleculin Biotech beats Estrella Immunopharma on 8 of the 12 factors compared between the two stocks.

How does Moleculin Biotech compare to Nabriva Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Moleculin Biotech has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Moleculin Biotech's return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 707.34%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Moleculin Biotech has higher earnings, but lower revenue than Nabriva Therapeutics. Moleculin Biotech is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

In the previous week, Moleculin Biotech had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 0 mentions for Nabriva Therapeutics. Moleculin Biotech's average media sentiment score of 0.30 beat Nabriva Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Nabriva Therapeutics	Neutral

Summary

Moleculin Biotech beats Nabriva Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.55M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.15	20.05	24.05	24.76
Price / Sales	N/A	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.58	8.16	10.69	6.90
Net Income	-$33.56M	$23.89M	$3.57B	$337.45M
7 Day Performance	10.32%	3.66%	1.56%	2.84%
1 Month Performance	29.15%	1.69%	2.49%	4.78%
1 Year Performance	-83.02%	46.95%	26.51%	33.08%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	2.4819 of 5 stars	$2.73 +3.2%	$22.00 +707.3%	-83.6%	$14.55M	N/A	N/A	20	Short Interest Increase
MGX Metagenomi	3.1117 of 5 stars	$1.33 flat	$9.00 +576.7%	-16.1%	$50.07M	$25.21M	N/A	236	News Coverage Analyst Upgrade Gap Down
GNTA Genenta Science	0.4507 of 5 stars	$2.11 -4.1%	N/A	-51.7%	$49.78M	N/A	N/A	7
ATYR aTyr Pharma	3.7333 of 5 stars	$0.50 -3.8%	$25.67 +5,032.3%	-91.5%	$49.04M	$190K	N/A	53	Gap Up
ESLA Estrella Immunopharma	2.8161 of 5 stars	$1.07 -1.4%	$8.00 +651.2%	+10.4%	$45.83M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. MGX, GNTA, ATYR, ESLA, and NBRV

How does Moleculin Biotech compare to Metagenomi?

Summary

How does Moleculin Biotech compare to Genenta Science?

Summary

How does Moleculin Biotech compare to aTyr Pharma?

Summary

How does Moleculin Biotech compare to Estrella Immunopharma?

Summary

How does Moleculin Biotech compare to Nabriva Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. MGX, GNTA, ATYR, ESLA, and NBRV

How does Moleculin Biotech compare to Metagenomi?

Does the media favor MGX or MBRX?

Which has higher valuation and earnings, MGX or MBRX?

Which has more risk & volatility, MGX or MBRX?

Do institutionals & insiders hold more shares of MGX or MBRX?

Is MGX or MBRX more profitable?

Do analysts recommend MGX or MBRX?

Summary

How does Moleculin Biotech compare to Genenta Science?

Does the media prefer MBRX or GNTA?

Which has preferable earnings & valuation, MBRX or GNTA?

Which has more risk & volatility, MBRX or GNTA?

Do analysts rate MBRX or GNTA?

Is MBRX or GNTA more profitable?

Do insiders and institutionals believe in MBRX or GNTA?

Summary

How does Moleculin Biotech compare to aTyr Pharma?

Is ATYR or MBRX more profitable?

Does the media favor ATYR or MBRX?

Do institutionals & insiders believe in ATYR or MBRX?

Which has stronger valuation & earnings, ATYR or MBRX?

Which has more risk and volatility, ATYR or MBRX?

Do analysts rate ATYR or MBRX?

Summary

How does Moleculin Biotech compare to Estrella Immunopharma?

Do analysts recommend MBRX or ESLA?

Which has stronger earnings and valuation, MBRX or ESLA?

Which has more volatility & risk, MBRX or ESLA?

Is MBRX or ESLA more profitable?

Do institutionals & insiders believe in MBRX or ESLA?

Does the media prefer MBRX or ESLA?

Summary

How does Moleculin Biotech compare to Nabriva Therapeutics?

Which has more risk & volatility, MBRX or NBRV?

Do institutionals and insiders believe in MBRX or NBRV?

Is MBRX or NBRV more profitable?

Do analysts rate MBRX or NBRV?

Which has stronger valuation & earnings, MBRX or NBRV?

Does the media prefer MBRX or NBRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools